Antipsychotic Polypharmacy in Schizophrenia

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2008

Conditions
Schizophrenia
Interventions
DRUG

2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)

"Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period."

DRUG

main antipsychotic medication and placebo

"The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician."

Trial Locations (1)

M5T 1R8

Centre for Addiction and Mental Health, Toronto

All Listed Sponsors
collaborator

Canadian Psychiatric Research Foundation

OTHER

lead

Centre for Addiction and Mental Health

OTHER

NCT00493233 - Antipsychotic Polypharmacy in Schizophrenia | Biotech Hunter | Biotech Hunter